Elicera Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Other Revenue	10.86	7.13	11.23	1.28	0	Upgrade
Revenue	10.86	7.13	11.23	1.28	0	Upgrade
Revenue Growth (YoY)	52.28%	-36.52%	777.23%	217987.39%	-	Upgrade
Gross Profit	10.86	7.13	11.23	1.28	0	Upgrade
Selling, General & Admin	28.8	24	28.31	20.63	13.11	Upgrade
Operating Expenses	28.8	24.01	28.33	20.64	13.12	Upgrade
Operating Income	-17.94	-16.88	-17.1	-19.36	-13.12	Upgrade
Interest Expense	-0.01	-0.05	-0.08	-0.13	-0	Upgrade
Interest & Investment Income	0.55	0.83	0.77	0.05	-	Upgrade
Other Non Operating Income (Expenses)	-	0	-	-	0	Upgrade
EBT Excluding Unusual Items	-17.41	-16.11	-16.4	-19.44	-13.12	Upgrade
Pretax Income	-17.41	-16.11	-16.4	-19.44	-13.12	Upgrade
Net Income	-17.41	-16.11	-16.4	-19.44	-13.12	Upgrade
Net Income to Common	-17.41	-16.11	-16.4	-19.44	-13.12	Upgrade
Shares Outstanding (Basic)	46	32	20	20	16	Upgrade
Shares Outstanding (Diluted)	46	32	20	20	16	Upgrade
Shares Change (YoY)	44.30%	59.89%	-0.40%	23.97%	32.98%	Upgrade
EPS (Basic)	-0.38	-0.51	-0.83	-0.98	-0.82	Upgrade
EPS (Diluted)	-0.38	-0.51	-0.83	-0.98	-0.82	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-165.31%	-236.86%	-152.24%	-1512.51%	-2234986.20%	Upgrade
Profit Margin	-160.35%	-226.01%	-146.02%	-1518.44%	-2235169.17%	Upgrade
EBITDA	-17.93	-16.87	-17.08	-19.35	-13.11	Upgrade
EBITDA Margin	-165.20%	-236.70%	-152.13%	-	-	Upgrade
D&A For EBITDA	0.01	0.01	0.01	0.01	0.01	Upgrade
EBIT	-17.94	-16.88	-17.1	-19.36	-13.12	Upgrade
EBIT Margin	-165.31%	-236.86%	-152.24%	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.